Stage IIB osteogenic sarcoma.
Two hundred seventy-one consecutive patients treated from 1976 through 1986 were reviewed to estimate long-term survival. Disease-free survival for the entire cohort was 77% at five years and 74% at ten years. Humeral lesions had the best probability of survival (84% at ten years), followed by tibial lesions (81%) and femoral lesions (67%). Histologic response to preoperative chemotherapy was the strongest predictor of outcome. Those with little response had a survival estimate of 54% at ten years as compared to 68% for partial responders and approximately 90% for complete responders. Local recurrence was seen in 6.6% and was associated with an adverse effect on survival. Only two of the 18 patients with local recurrence have been rendered long-term disease-free survivors.
Glasser
D B
DB
Memorial Sloan-Kettering Cancer Center, New York, New York.
Lane
J M
JM
D000293:Adolescent; D000328:Adult; D000671:Amputation, Surgical / Q000592:standards* / Q000706:statistics & numerical data / Q000639:trends; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D001859:Bone Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D002648:Child; D002675:Child, Preschool; D002985:Clinical Protocols; D015331:Cohort Studies; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D003609:Dactinomycin / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D009519:New York City / Q000453:epidemiology; D012516:Osteosarcoma / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D010027:Osteotomy / Q000592:standards* / Q000706:statistics & numerical data; D011182:Postoperative Care / Q000592:standards; D011237:Predictive Value of Tests; D011300:Preoperative Care / Q000592:standards; D016019:Survival Analysis; D015996:Survival Rate
D001761:Bleomycin; D003609:Dactinomycin; D004317:Doxorubicin; D003520:Cyclophosphamide; D008727:Methotrexate